At ~$2/Sh Jefferies Sees a Compelling Entry Point in Dynavax (DVAX)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Dynavax (DVAX) Fails to Win FDA Panel Backing on Heplisav for Hep B
November 15, 2012 1:52 PM ESTFDA advisors vote 8-5 that Dynavax Technologies Corporation (NASDAQ: DVAX) Heplisav vaccine unsafe as Hep B treatment. The panel said the vaccine hasn't shown enough safety.
Shares of Dynavax are currently halted.... More
